# Questions to Ask a Healthcare Startup Founder During Due Diligence (2026 Investor Guide) > Knowing exactly which questions to ask a healthcare startup founder separates serious investors from those who get burned. This guide gives you a battle-tested framework covering regulatory status, clinical evidence, reimbursement, IP, and team, with primary sources to verify every answer. ## What Is the Single Most Important Frame Before You Start Asking Questions? Verify before you trust. Every answer a founder gives you is a hypothesis until you confirm it against a primary source. Build your question list around four pillars: regulatory standing, clinical and commercial evidence, intellectual property, and financial durability. Then check FDA databases, SEC EDGAR, ClinicalTrials.gov, USPTO, and PubMed before you write a check. --- ## What Regulatory Questions Must You Ask First? Regulatory status is the single biggest binary risk in healthcare investing. Ask these questions and verify each answer independently. **Ask the founder:** - What is the exact regulatory pathway you are pursuing or have completed (510(k), De Novo, PMA, IND, NDA, BLA, EUA, or no FDA oversight required)? - Have you received any FDA correspondence, including warning letters, untitled letters, or complete response letters? Can I see them? - If you claim exempt or non-device status, what legal opinion supports that classification? - For SaMD (software as a medical device) products: have you reviewed your classification under the FDA's Digital Health Center of Excellence guidance current as of 2026? **Where to verify:** - FDA 510(k) database (accessdata.fda.gov) for cleared devices - FDA PMA database for approved devices - FDA Warning Letters database for enforcement history - FDA drug approval databases (Drugs@FDA) for pharmaceutical products - ClinicalTrials.gov to confirm trial registration matches what the founder describes A founder who cannot produce the actual FDA submission number or who describes a regulatory pathway inconsistently across conversations is a serious red flag. --- ## What Clinical Evidence Questions Reveal True Product Strength? Clinical claims are the most frequently overstated area in healthcare startup pitches. Probe the evidence hard. **Ask the founder:** - What is the study design behind your efficacy claims: randomized controlled trial, single-arm cohort, retrospective chart review, or in-house analytics? - What was the comparator arm, if any, and what was the patient population size? - Have your results been published in a peer-reviewed journal? What is the journal's impact factor and was the study independently conducted? - What does your real-world outcomes data show since launch, and how does it differ from your trial data? - Have any independent researchers replicated or challenged your findings? **Where to verify:** - PubMed (pubmed.ncbi.nlm.nih.gov) to pull the actual publications and check authorship conflicts - ClinicalTrials.gov to confirm the registered endpoints match the published results (outcome switching is common) - Google Scholar for independent citations and critiques --- ## How Do You Probe Reimbursement and Revenue Sustainability? A product without a reimbursement path is a product without a scalable business in most healthcare markets. This is the area most early-stage investors under-examine. **Ask the founder:** - Do you have an existing CPT, HCPCS, or ICD code that covers your product, or are you pursuing a new code? What is the timeline and who is sponsoring the application? - What percentage of your current revenue comes from fee-for-service reimbursement versus direct contracts versus cash pay? - Have any payers denied coverage, and what was the stated clinical rationale? - If you are selling to health systems, what does the contract structure look like and what are your average sales cycle length and net payment terms? **Where to verify:** - CMS coverage database (cms.gov) for Medicare coverage determinations - CMS CLFS and PFS fee schedules for reimbursement rates - Check payer medical policies directly on major payer websites for coverage language --- ## What Intellectual Property Questions Protect Your Investment? IP durability determines whether a market lead can be defended. Do not rely on founder summaries. **Ask the founder:** - What patents do you hold, what is the grant date, and when do they expire? - Are any patents pending, and what is the likelihood of grant based on prior art searches you have conducted? - Do you have freedom-to-operate opinions from outside counsel for your core technology? - Have you experienced any IP challenges, inter partes reviews, or litigation threats? - Who owns IP created by co-founders, contractors, and employees, and are assignment agreements in place? **Where to verify:** - USPTO Patent Full-Text Database (patents.google.com or USPTO.gov) to pull grant status and claims - USPTO PAIR system for pending application status - Review assignment records to confirm ownership transferred to the company, not individuals --- ## What Team and Execution Questions Separate Real Operators From Storytellers? Healthcare startups fail most often on execution, not on science. Ask questions that expose operational reality. **Ask the founder:** - What is your quality management system and have you passed any FDA inspections or third-party audits? - Who on your team has previously navigated a full FDA submission and can you introduce me to that person directly? - What were the three biggest mistakes you made in the last 12 months and what specifically changed as a result? - Who are your key advisors and what hours per month do they actually commit? - What does your 18-month cash runway look like under a scenario where your next regulatory milestone is delayed by six months? --- ## Due Diligence Checklist: 10 Items Before Any Healthcare Investment 1. Confirm regulatory status in FDA databases, not from the pitch deck 2. Pull all ClinicalTrials.gov registrations and compare endpoints to publications 3. Read the actual peer-reviewed studies, not summaries 4. Verify patent ownership and expiry dates on USPTO directly 5. Confirm CMS coverage status or identify the specific coverage risk 6. Check FDA enforcement database for warning letters or recalls 7. Pull any SEC filings if the company has issued securities (EDGAR at sec.gov) 8. Request and review quality management documentation 9. Speak independently to at least two clinical users, not founder-provided references 10. Model a six-month regulatory delay scenario into your financial assumptions --- ## How Can You Automate This Research Before the First Founder Meeting? Manually checking six regulatory databases and cross-referencing patent records before every meeting is time-intensive. MedFuel Intel builds AI-powered due diligence reports that pull from FDA databases, ClinicalTrials.gov, USPTO, PubMed, and SEC EDGAR automatically, flagging discrepancies between what founders claim and what primary sources show. Run a free Red Flag Screener on any healthcare company at https://medfuelintel.com before your next founder call so you walk in with verified facts, not founder framing. --- *Informational only, not investment advice.* --- Source: MedFuel Intel (https://www.medfuelintel.com/geo/article/questions-to-ask-a-healthcare-startup-founder-during-due-diligence). Grounded in primary-source-verified events; verify against SEC, FDA, and ClinicalTrials.gov before any investment decision.